Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Sebi imposes Rs 30...

    Sebi imposes Rs 30 lakh fine on Plethico Pharma, 3 others

    Written by supriya kashyap kashyap Published On 2017-10-30T12:06:47+05:30  |  Updated On 30 Oct 2017 12:06 PM IST
    Sebi imposes Rs 30 lakh fine on Plethico Pharma, 3 others

    New Delhi: Markets regulator Sebi imposed Rs 30 lakh fine on Plethico Pharmaceuticals and its three senior officials for disclosure lapses and failure to redeem Foreign Currency Convertible Bonds (FCCBs) issued to investors.


    These officials are Shashikant Patel, chairman and managing director; Chirag Patel, whole time director; Gauravi Parikh, executive director.


    The Sebi order follows a complaint from Economic Offences Wing in respect of default of Plethico Pharma in redeeming the FCCBs and failure to disclose it stock exchanges.


    The Securities and Exchange Board of India (Sebi) had carried out investigation for October 23, 2012 which was the date of default in redemption of FCCBs to find out the possible violations.


    The probe found that these entities failed to disclose about raising of money through FCCBs and subsequently non redemption of FCCBs despite the maturity date.


    By indulging in such activities, they violated Code of Corporate Disclosure Practices under Prevention of Insider Trading (PIT) Regulations as well as Listing Agreement.


    "Not making disclosures regarding raising of money through FCCBs and subsequently non redemption of FCCBs despite maturity date, are certainly affecting the rights of the investors /bondholders and justifiable penalty needs to be imposed upon the noticees to meet the ends of justice," Sebi General Manager and Adjudicating Officer Rachna Anand said.


    Accordingly, the regulator levied the fine on them.

    Chirag PatelEconomic Offences WingForeign Currency Convertible BondGauravi ParikhPlethico PharmaPrevention of Insider TradingSEBISecurities and Exchange Board of IndiaShashikant Patel
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok